ASH 2021 | Stratifying patients receiving CAR-T cell therapy with CAR-HEMATOTOX
Kai Rejeski
• 12 Dec 2021
Kai Rejeski, MD, LMU Hospital Munich, Munich, Germany, discusses the use of the CAR-HEMATOTOX score to identify patients who are at risk of non-relapse mortality post-chimeric antigen receptor (CAR) T-cell therapy. In a retrospective analysis, patients were evaluated 90 days after CAR-T treatment and patients with a high score were at a higher risk of developing severe neutropenia and bacterial infections, as well have lower rates of progression-free survival. Stratifying patients based on their CAR-HEMATOTOX score can result in certain patients appropriately receiving anti-infective prophylaxis or G-CSF. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
